- Home
- IMAB vs NXC Comparison
IMAB vs NXC Comparison
Compare IMAB & NXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- NXC
- Stock Information
- Founded
- IMAB 2014
- NXC 1992
- Country
- IMAB United States
- NXC United States
- Employees
- IMAB N/A
- NXC N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- NXC Investment Managers
- Sector
- IMAB Health Care
- NXC Finance
- Exchange
- IMAB Nasdaq
- NXC Nasdaq
- Market Cap
- IMAB 83.8M
- NXC 82.6M
- IPO Year
- IMAB 2020
- NXC N/A
- Fundamental
- Price
- IMAB $1.07
- NXC $13.03
- Analyst Decision
- IMAB Strong Buy
- NXC
- Analyst Count
- IMAB 3
- NXC 0
- Target Price
- IMAB $8.00
- NXC N/A
- AVG Volume (30 Days)
- IMAB 682.1K
- NXC 17.5K
- Earning Date
- IMAB 03-13-2025
- NXC 01-01-0001
- Dividend Yield
- IMAB N/A
- NXC 3.97%
- EPS Growth
- IMAB N/A
- NXC N/A
- EPS
- IMAB N/A
- NXC 0.19
- Revenue
- IMAB $3,313,984.00
- NXC N/A
- Revenue This Year
- IMAB N/A
- NXC N/A
- Revenue Next Year
- IMAB N/A
- NXC N/A
- P/E Ratio
- IMAB N/A
- NXC $70.47
- Revenue Growth
- IMAB N/A
- NXC N/A
- 52 Week Low
- IMAB $0.84
- NXC $11.86
- 52 Week High
- IMAB $2.08
- NXC $13.70
- Technical
- Relative Strength Index (RSI)
- IMAB 55.17
- NXC 44.19
- Support Level
- IMAB $1.00
- NXC $12.90
- Resistance Level
- IMAB $1.20
- NXC $13.09
- Average True Range (ATR)
- IMAB 0.12
- NXC 0.10
- MACD
- IMAB 0.02
- NXC 0.01
- Stochastic Oscillator
- IMAB 40.97
- NXC 59.09
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing primarily in municipal obligations.